Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma (NCT02520791)
A Phase I Trial of MEDI-570 in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
🩺 Plain-English Summary (8th-Grade Level)
This phase I trial studies the side effects and best dose of anti-inducible T-cell co-stimulator (ICOS) monoclonal antibody MEDI-570 in treating patients with peripheral T-cell lymphoma follicular variant or angioimmunoblastic T-cell lymphoma that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as anti-ICOS monoclonal antibody MEDI-570, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread.
Who can join: Review the eligibility criteria below.
Location: City of Hope Comprehensive Cancer Center — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (23 Sites)
- City of Hope Comprehensive Cancer Center — Duarte, California
- University of California Davis Comprehensive Cancer Center — Sacramento, California
- Smilow Cancer Center/Yale-New Haven Hospital — New Haven, Connecticut
- Yale University — New Haven, Connecticut
- Moffitt Cancer Center — Tampa, Florida
- University of Chicago Comprehensive Cancer Center — Chicago, Illinois
- University of Kansas Clinical Research Center — Fairway, Kansas
- University of Kentucky/Markey Cancer Center — Lexington, Kentucky
- Siteman Cancer Center at West County Hospital — Creve Coeur, Missouri
- Washington University School of Medicine — St Louis, Missouri
- Siteman Cancer Center-South County — St Louis, Missouri
- University of Nebraska Medical Center — Omaha, Nebraska
- Roswell Park Cancer Institute — Buffalo, New York
- Montefiore Medical Center-Einstein Campus — The Bronx, New York
- Montefiore Medical Center-Weiler Hospital — The Bronx, New York
- Montefiore Medical Center - Moses Campus — The Bronx, New York
- Duke University Medical Center — Durham, North Carolina
- Ohio State University Comprehensive Cancer Center — Columbus, Ohio
- UT Southwestern/Simmons Cancer Center-Dallas — Dallas, Texas
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center — Houston, Texas
- Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
- BCCA-Vancouver Cancer Centre — Vancouver, British Columbia
- University Health Network-Princess Margaret Hospital — Toronto, Ontario
📞 Contact the Study Coordinator
Phone: (800) 826-4673
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.